Table 1.
Patient demographics relating to biopsy tissue samples used in mRNA, miRNA, and protein analyses
| Placebo group | Zinc supplement group | |||
|---|---|---|---|---|
| n | % of total | n | % of total | |
| mRNA study | ||||
| Age | ||||
| 40–49 | 2 | 40.0 | 0 | 0.0 |
| 50–59 | 1 | 20.0 | 2 | 40.0 |
| 60–69 | 2 | 40.0 | 1 | 20.0 |
| 70 + | 0 | 0.0 | 2 | 40.0 |
| Gender | ||||
| Female | 2 | 40.0 | 3 | 60.0 |
| Male | 3 | 60.0 | 2 | 40.0 |
| Ethnicity | ||||
| Caucasian | 4 | 80.0 | 5 | 100.0 |
| African American | 0 | 0.0 | 0 | 0.0 |
| Hispanic | 1 | 20.0 | 0 | 0.0 |
| Asian | 0 | 0.0 | 0 | 0.0 |
| Barrett’s segment length | ||||
| 1 cm | 1 | 20.0 | 2 | 40.0 |
| 2 cm | 4 | 80.0 | 2 | 40.0 |
| 3 cm | 0 | 0.0 | 0 | 0.0 |
| > 3 cm | 0 | 0.0 | 1 | 20.0 |
| Proton pump inhibitor use | ||||
| Omeprazole | 2 | 40.0 | 4 | 80.0 |
| Esomeprazole | 0 | 0.0 | 1 | 20.0 |
| Pantoprazole | 2 | 40.0 | 0 | 0.0 |
| Lansoprazole | 1 | 20.0 | 0 | 0.0 |
| Dexlansoprazole | 0 | 0.0 | 0 | 0.0 |
| miRNA study | ||||
| Age | ||||
| 40–49 | 2 | 33.3 | 0 | 0.0 |
| 50–59 | 1 | 16.7 | 0 | 0.0 |
| 60–69 | 3 | 50.0 | 5 | 83.3 |
| 70 + | 0 | 0.0 | 1 | 16.7 |
| Gender | ||||
| Female | 2 | 33.3 | 4 | 66.7 |
| Male | 4 | 66.7 | 2 | 33.3 |
| Ethnicity | ||||
| Caucasian | 4 | 66.7 | 6 | 100.0 |
| African American | 1 | 16.7 | 0 | 0.0 |
| Hispanic | 1 | 16.7 | 0 | 0.0 |
| Asian | 0 | 0.0 | 0 | 0.0 |
| Barrett’s segment length | ||||
| 1 cm | 2 | 33.3 | 1 | 16.7 |
| 2 cm | 3 | 50.0 | 3 | 50.0 |
| 3 cm | 0 | 0.0 | 1 | 16.7 |
| > 3 cm | 1 | 16.7 | 1 | 16.7 |
| Proton pump inhibitor use | ||||
| Omeprazole | 3 | 50.0 | 4 | 66.7 |
| Esomeprazole | 1 | 16.7 | 1 | 16.7 |
| Pantoprazole | 1 | 16.7 | 0 | 0.0 |
| Lansoprazole | 1 | 16.7 | 1 | 16.7 |
| Protein study: BAX | ||||
| Age | ||||
| 40–49 | 0 | 25.0 | 1 | 25.0 |
| 50–59 | 1 | 0.0 | 1 | 25.0 |
| 60–69 | 2 | 25.0 | 0 | 25.0 |
| 70 + | 1 | 50.0 | 2 | 25.0 |
| Gender | ||||
| Female | 2 | 50.0 | 0 | 50.0 |
| Male | 2 | 50.0 | 4 | 50.0 |
| Ethnicity | ||||
| Caucasian | 4 | 100.0 | 4 | 100.0 |
| African American | 0 | 0.0 | 0 | 0.0 |
| Hispanic | 0 | 0.0 | 0 | 0.0 |
| Asian | 0 | 0.0 | 0 | 0.0 |
| Barrett’s segment length | ||||
| 1 cm | 2 | 75.0 | 0 | 75.0 |
| 2 cm | 2 | 0.0 | 1 | 25.0 |
| 3 cm | 0 | 0.0 | 0 | 0.0 |
| > 3 cm | 0 | 25.0 | 3 | 0.0 |
| Proton pump inhibitor use** | ||||
| Omeprazole | 1 | 50.0 | 1 | 33.3 |
| Esomeprazole | 0 | 0.0 | 2 | 33.3 |
| Pantoprazole | 2 | 50.0 | 0 | 0.0 |
| Lansoprazole | 0 | 0.0 | 1 | 33.3 |
| Protein study: claudin | ||||
| Age | ||||
| 40–49 | 1 | 25.0 | 1 | 25.0 |
| 50–59 | 0 | 0.0 | 1 | 25.0 |
| 60–69 | 1 | 25.0 | 1 | 25.0 |
| 70 + | 2 | 50.0 | 1 | 25.0 |
| Gender | ||||
| Female | 2 | 50.0 | 2 | 50.0 |
| Male | 2 | 50.0 | 2 | 50.0 |
| Ethnicity | ||||
| Caucasian | 4 | 100.0 | 4 | 100.0 |
| African American | 0 | 0.0 | 0 | 0.0 |
| Hispanic | 0 | 0.0 | 0 | 0.0 |
| Asian | 0 | 0.0 | 0 | 0.0 |
| Barrett’s segment length | ||||
| 1 cm | 3 | 75.0 | 3 | 75.0 |
| 2 cm | 0 | 0.0 | 1 | 25.0 |
| 3 cm | 0 | 0.0 | 0 | 0.0 |
| > 3 cm | 1 | 25.0 | 0 | 0.0 |
| Proton pump inhibitor use | ||||
| Omeprazole | 2 | 50.0 | 2 | 50.0 |
| Esomeprazole | 0 | 0.0 | 1 | 25.0 |
| Pantoprazole | 2 | 50.0 | 0 | 0.0 |
| Lansoprazole | 0 | 0.0 | 1 | 25.0 |
**1 patient in the placebo group was not taking any PPI medication